Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Debt Ratio (2016 - 2025)

Historic Debt Ratio for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 0.61.

  • ImmunityBio's Debt Ratio fell 1884.71% to 0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.61, marking a year-over-year decrease of 1884.71%. This contributed to the annual value of 0.74 for FY2024, which is 14106.81% up from last year.
  • As of Q3 2025, ImmunityBio's Debt Ratio stood at 0.61, which was down 1884.71% from 0.76 recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Debt Ratio ranged from a high of 1.5 in Q1 2021 and a low of 0.31 during Q4 2023
  • In the last 5 years, ImmunityBio's Debt Ratio had a median value of 0.76 in 2025 and averaged 0.87.
  • In the last 5 years, ImmunityBio's Debt Ratio surged by 2230531.88% in 2021 and then crashed by 4721.17% in 2022.
  • ImmunityBio's Debt Ratio (Quarter) stood at 0.65 in 2021, then surged by 61.89% to 1.06 in 2022, then crashed by 70.87% to 0.31 in 2023, then soared by 141.07% to 0.74 in 2024, then fell by 17.98% to 0.61 in 2025.
  • Its Debt Ratio stands at 0.61 for Q3 2025, versus 0.76 for Q2 2025 and 0.98 for Q1 2025.